Koninklijke Philips Adr Each Rep 1 Ord Eur0.20 (PHG) Stock
Global health technology company powering hospital diagnostics and care. Here's the price, business snapshot, and what's worth knowing about Koninklijke Philips Adr Each Rep 1 Ord Eur0.20 in August 2026.
Koninklijke Philips N.V. (PHG) is a Dutch health‑technology company that designs and sells medical devices and related services across diagnostic imaging, patient monitoring, and respiratory care. After refocusing away from consumer appliances, Philips now emphasises hospital equipment, connected care and health informatics — areas driven by ageing populations and digital healthcare adoption. Investors should note a market capitalisation around $27.5 billion and a business mix of product sales, long‑term service contracts and software subscriptions, which can smooth revenues but requires sustained R&D and capital investment. Key considerations include regulatory scrutiny, product quality and lingering legal exposures from past device issues, alongside competition from larger medical‑device peers. Financial metrics to watch are order backlog, service revenue growth, margins and free cash flow. This is general information for educational purposes only; it is not investment advice and investors should assess suitability against their own objectives and risk tolerance.
Why It’s Moving
PHG is moving more on analyst disagreement and broader sector mood than on a fresh company catalyst.
- Analyst sentiment on PHG remains mixed but cautious, with recent consensus readings clustering around Hold even as some models still imply meaningful upside. That gap suggests investors are weighing valuation against the company’s underlying recovery potential.
- Recent forecast ranges vary widely across providers, showing that conviction is low and the stock is still being re-rated rather than clearly re-accelerating. Wide target dispersion typically signals uncertainty around earnings visibility and execution.
- There were no clear major company-specific headlines in the last 7 days, so the stock is likely being driven more by analyst positioning and broader healthcare-sector sentiment than by a fresh catalyst.
PHG is moving more on analyst disagreement and broader sector mood than on a fresh company catalyst.
- Analyst sentiment on PHG remains mixed but cautious, with recent consensus readings clustering around Hold even as some models still imply meaningful upside. That gap suggests investors are weighing valuation against the company’s underlying recovery potential.
- Recent forecast ranges vary widely across providers, showing that conviction is low and the stock is still being re-rated rather than clearly re-accelerating. Wide target dispersion typically signals uncertainty around earnings visibility and execution.
- There were no clear major company-specific headlines in the last 7 days, so the stock is likely being driven more by analyst positioning and broader healthcare-sector sentiment than by a fresh catalyst.
When is the next earnings date for KONINKLIJKE PHILIPS NV ADR EACH REP 1 ORD EUR0.20 (PHG)?
The next earnings date for PHG is expected on July 28, 2026, before the market opens. The report will cover Q2 2026 results, ending June 2026. This date is based on the company’s typical reporting pattern and is the most recently indicated estimate available.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Philips stock, with a target price indicating potential for growth.
Financial Health
Philips is performing well with solid revenue and cash flow, though margins could improve.
Dividend
Philips' below average dividend yield of 0.99% may not be appealing for dividend-seeking investors. If you invested $1000 you would be paid $9.90 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring PHG
Healthcare Innovation: MedTech Giants Portfolio 2025
Growing demand for advanced healthcare in Africa highlights the global companies at the forefront of medical technology innovation. This theme offers exposure to US and EU-listed industry leaders in robotic surgery, diagnostic imaging, and other medical devices.
Published: 22 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Recurring revenue mix
Services and software subscriptions can stabilise revenue streams, though growth depends on hospital budgets and successful product roll‑outs.
Global healthcare trends
Ageing populations and digital health uptake support long‑term demand, while emerging‑market expansion offers opportunity amid local competition.
Regulatory and quality focus
Product safety and regulatory compliance are critical; past device issues highlight the potential for reputational and financial impact.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
